05:04 AM EDT, 10/20/2026 (MT Newswires) -- Navamedic (NAVA.OL) extended its Nordic distribution and marketing rights for the Mysimba obesity drug for another five years. The Nordic healthcare products provider said Tuesday that the agreement with Mysimba's new owner, Azurity Pharmaceuticals, largely maintains the original contract terms and includes an upfront licensing fee. The extension will take effect on April 26, 2027.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.